Compared with PBS, the tier 1 neoantigen vaccine alone and anti-PD-1 combination therapy significantly reduced tumor growth (tier 1: p < 0.001, tier 1 + anti-PD-1: p < 0.001) (Supplementary Fig. 7c). The gene discussed is PDCD1; the disease is neoplasm.